What is William Blair’s Forecast for Neurogene Q1 Earnings?

Neurogene Inc. (NASDAQ:NGNE) – Equities research analysts at William Blair issued their Q1 2025 earnings per share estimates for Neurogene in a report released on Tuesday, March 25th. William Blair analyst S. Corwin expects that the company will post earnings of ($0.92) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. William Blair also issued estimates for Neurogene’s Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.93) EPS, Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($3.70) EPS and FY2026 earnings at ($4.60) EPS.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.99) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.05. The company had revenue of $0.93 million during the quarter.

Separately, HC Wainwright cut their price target on shares of Neurogene from $55.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Neurogene currently has an average rating of “Buy” and a consensus price target of $59.80.

Neurogene Stock Performance

Shares of NASDAQ:NGNE opened at $15.33 on Thursday. The company’s fifty day moving average is $16.92 and its 200-day moving average is $28.96. Neurogene has a 52 week low of $13.47 and a 52 week high of $74.49. The company has a market capitalization of $227.73 million, a PE ratio of -3.59 and a beta of 1.01.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. PNC Financial Services Group Inc. bought a new stake in shares of Neurogene during the fourth quarter worth $71,000. China Universal Asset Management Co. Ltd. acquired a new stake in Neurogene in the fourth quarter worth about $72,000. Virtus ETF Advisers LLC raised its holdings in Neurogene by 45.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,183 shares of the company’s stock worth $73,000 after purchasing an additional 989 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Neurogene by 192.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company’s stock worth $91,000 after purchasing an additional 1,429 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its position in Neurogene by 34.5% during the 4th quarter. Wells Fargo & Company MN now owns 5,444 shares of the company’s stock valued at $124,000 after purchasing an additional 1,397 shares during the period. Institutional investors and hedge funds own 52.37% of the company’s stock.

Insider Activity

In other news, CFO Christine Mikail Cvijic sold 4,501 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $16.94, for a total transaction of $76,246.94. Following the sale, the chief financial officer now directly owns 72,343 shares of the company’s stock, valued at $1,225,490.42. This represents a 5.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 9.92% of the stock is currently owned by corporate insiders.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.